<DOC>
	<DOCNO>NCT02019966</DOCNO>
	<brief_summary>Antiviral resistance remain important issue long-term NA therapy . For lamivudine ( LAM ) , rtM204V/I rtL180M mutation occur 70 % 5 year therapy . In Korea , primarily owe limited subsidization policy health insurance system , many patient LMV-resistance treat either rescue ADV ETV 1.0 mg monotherapy , ultimately lead high prevalence MDR strain . For patient , rescue therapy combine ADV either ETV LAM try , frequently suboptimal response . Rescue TDF monotherapy TDF-based combination therapy available Korea patient `` difficult-to-treat '' antiviral resistance owe prior treatment failure . However , well evaluate yet . A long-term efficacy safety TDF-based rescue therapy real practice patient necessary revise Korean guideline treatment chronic hepatitis B near future .</brief_summary>
	<brief_title>A Korean Cohort Study TDF Rescue Therapy Difficult-to-treat CHB Patients : Comparison Between TDF Monotherapy TDF-based Combination Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>20 year old adult chronic hepatitis B patient treat tenofovir alone tenofovir base combination therapy previous treatment failure patient agree sing consent form coinfected patient HCV , HDV HIV pregnancy breast feed woman female patient plan pregnant past history hepatocellular carcinoma combine liver disease include wilson , alcoholic , NASH , alpha1 antitrypsin deficiency liver disease . patient hypersensitivity drug patient enrol clinical study within 60 day patient eligible clinical study accord investor</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>